Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT05996029 |
Other study ID # |
K4011 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
August 2023 |
Est. completion date |
June 2024 |
Study information
Verified date |
May 2023 |
Source |
Peking Union Medical College Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
According to the "China Smoking Health Hazard Report 2020", the total number of smokers in
China is estimated to be 350 million, of which 180 million are already addicted. In addition,
more than 700 million nonsmokers are exposed to secondhand smoke and become passive smoking
victims, among which the family is one of the main places of secondhand smoke exposure, and
mothers and children are the most affected group.
Passive smoking is a risk factor for spontaneous abortion in pregnant women and an important
risk factor for the occurrence of gestational hypertension syndrome and pregnancy
complications, and it also affects embryonic development with adverse pregnancy outcomes such
as miscarriage, stillbirth, intrauterine growth retardation, preterm birth, immune
deficiency, birth defects, and mental retardation.
Helping smokers quit is the fundamental solution to reducing secondhand smoke exposure. The
accessibility and effectiveness of traditional offline smoking cessation intervention
services do not meet the needs of society. With the development of mobile communication
technology, digital cessation such as SMS cessation, WeChat cessation, and APP cessation have
emerged, which combine clinical cessation guidelines with software technology and present
rich product features and interactive design, providing a new solution to expand the
accessibility of clinical cessation interventions and address the problem of secondhand smoke
exposure.We hope to explore the impact of different digital cessation tools and their
combinations on reducing smoking prevalence and maternal tobacco exposure.
Description:
This project is a two-arm, practical-utility randomized controlled trial.The study was
designed to enroll 2214 quitters, and maternal cessation of enrollment after completion of
the quitter enrollment.After self-reported exposure to secondhand smoke has been tested with
a free cotinine urine test and the pregnant woman has signed an informed consent, she invites
the smoker who is causing her secondhand smoke to quit, which may include her husband,
family, friends, colleagues, neighbors, etc., or the pregnant woman herself.
Invited smokers will choose a quit day within two weeks of enrollment, use a cognitive
behavioral therapy-based cessation package and online coaching from medical staff, as well as
additional digital cessation tools, and receive a 12-week follow-up (smoking/quit status).
Enrolled pregnant women will receive general education on maternal and child health
management and the dangers of tobacco, and will be encouraged to provide psychological
support and encouragement to invited quitters in the mini-program (provided both parties
volunteer). The pregnant women will receive a 16-week follow-up (secondhand smoke exposure).
At the end of the study, all pregnant women and those who self-report successful cessation
will receive a free cotinine test as an objective test of cessation effectiveness.